Rachel Zayas is the Founder and CEO of Active Genomes Expressed Diagnostics (AGED). She has a Masters in Biotechnology and Business from American University. Rachel focuses on early detection methods of liver cancer by creating disruptive genomic technologies. Rachel’s goal is to combat cancer health disparities and facilitate a system of equality in the field of genomics.
Rachel received an NSF I-corps grant to travel to 28 cities to understand the global burden of liver cancer. During this journey, she learned how to engage key thought leaders, pursued market research, and met incredible mentors and leaders along the way.
Rachel previously co-founded another biotechnology venture and worked at MIT developing gene silencing therapeutics. She has written two science fiction novels, and when she is not working, she likes to travel to Maine to recharge by the mountains and the beach.
Venture: Active Genomes Expressed Diagnostics (AGED) is developing a non-invasive method to track changes on the genome that correlate to liver cancer to provide hepatologists a more accurate and affordable screening method than current tests to improve patient compliance and decrease late-stage diagnosis.